G

Galmed Pharmaceuticals Ltd
D

GLMD

3.05000
USD
0.02
(0.66%)
Market Open
Volume
10
EPS
-1
Div Yield
-
P/E
0
Market Cap
5,053,826
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    0.250
    (1.48%)
    17.130 USD
    A
    AMRN
    -0.02570
    (-5.37%)
    0.45300 USD
    BGNE
    BGNE
    0.590
    (0.33%)
    177.040 USD
    C
    CTMX
    -0.01500
    (-1.38%)
    1.07500 USD
    E
    EGRX
    0
    (0%)
    0.000000 USD
    F
    FGEN
    0.07080
    (17.39%)
    0.47800 USD
    J
    JAZZ
    1.280
    (1.04%)
    124.250 USD
    JNJ
    JNJ
    0.260
    (0.18%)
    144.570 USD
    L
    LIVN
    -0.780
    (-1.64%)
    46.840 USD
    M
    MYOV
    0
    (0%)
    0.000000 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    R
    RIGL
    -0.010
    (-0.06%)
    17.040 USD
    S
    SSNC
    -0.550
    (-0.73%)
    75.290 USD
    X
    XENE
    -0.250
    (-0.65%)
    38.340 USD
    X
    XNCR
    0.250
    (1.03%)
    24.410 USD
    More
News

Title: Galmed Pharmaceuticals Ltd

Sector: Healthcare
Industry: Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.